Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection

Journal of Central Nervous System Disease

Review

Maju Koola¹  Deanna L. Kelly¹  Heidi J. Wehring¹  Sheryl Thedford² 

[1] Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA.;University of Maryland School of Pharmacy, Baltimore, MD, USA.;

关键词: long acting injectable;    olanzapine;    schizophrenia;    patient perspective;    antipsychotic;   

DOI  :  10.4137/JCNSD.S4091

来源: Sage Journals

【 摘 要 】

Olanzapine long acting injection has joined risperidone and paliperidone as the second generation long acting antipsychotic injection options for treatment of patients with schizophrenia. Long acting injections are important alternatives to oral medications for patients who have difficulty adhering to daily or multiple daily medication administrations, yet may be underutilized or not well understood. Patient perceptions, adherence, and preferences are important issues for health care providers to address when discussing treatment options with their patients. Reviewed here are overall patient and health care provider attitudes and perceptions regarding long acting injections and the details of olanzapine long acting injectable, the newest agent, and how it will fit in the marketplace. In addition, efficacy, safety, dosing and use data regarding this newest long acting agent are reviewed and compared to other available long acting agents.

【 授权许可】

CC BY-NC   
© 2011 SAGE Publications.

【 图 表 】

Figure 1.